Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingArtivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Business segments
Jun 2026 · $125.8MThe company’s own SEC segment disclosure.
- Aortic Stent Grafts$46.4M37%
- On X$30.5M24%
- Preservation Services$25.9M21%
- Surgical Sealants$19.3M15%
- Other Products$3.7M3%
Artivion, Inc. (AORT) reported revenue of $116M in Q1 2026 (quarter ended Mar 31, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 65% and net income of $1.4M (1.2% of revenue). For the full year FY2025, revenue was $441M (+14% year on year) and net income $9.8M. Its largest product in Jun 2026 was Aortic Stent Grafts at $46M, 37% of the disclosed total, ahead of On X at 24%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.